Nicholas A. Vulpescu

Nicholas A. Vulpescu

Auto-generated profile, based on publicly available information

Nicholas A. Vulpescu

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2018 in Nature Genetics
Verified
Journal Article
Open access
2T23andMe Research Team
23andMe Research Team
JMJohn A. Morris
John A. Morris
JKJohn P. Kemp
John P. Kemp
SYScott E. Youlten
Scott E. Youlten
LLLaetitia Laurent
Laetitia Laurent
JRJ. Brent Richards
J. Brent Richards
Osteoporosis is a common aging-related disease diagnosed primarily using bone mineral density (BMD). We assessed genetic determinants of BMD as estimated by heel quantitative ultrasound in 426,824 individuals, identifying 518 genome-wide significant loci (301 novel), explaining 20% of its variance. We identified 13 bone fracture loci, all associated with estimated BMD (eBMD), in ~1.2 million individuals. We then identified target genes enriched for genes known to influence bone density and strength (maximum odds ratio (OR) = 58, P = 1 × 10-75) from cell-specific features, including chromatin conformation and accessible chromatin sites. We next performed rapid-throughput skeletal phenotyping of 126 knockout mice with disruptions in predicted target genes and found an increased abnormal skeletal phenotype frequency compared to 526 unselected lines (P < 0.0001). In-depth analysis of one gene, DAAM2, showed a disproportionate decrease in bone strength relative to mineralization. This genetic atlas provides evidence linking associated SNPs to causal genes, offers new insight into osteoporosis pathophysiology, and highlights opportunities for drug development.

18 November 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ZFZachariah H. Foda
Zachariah H. Foda
AAAkshaya V. Annapragada
Akshaya V. Annapragada
KBKavya Boyapati
Kavya Boyapati
DBDaniel C. Bruhm
Daniel C. Bruhm
NVNicholas A. Vulpescu
Nicholas A. Vulpescu
VVVictor E. Velculescu
Victor E. Velculescu
Liver cancer is a major cause of cancer mortality worldwide. Screening individuals at high risk, including those with cirrhosis and viral hepatitis, provides an avenue for improved survival, but current screening methods are inadequate. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome analyses to evaluate 724 individuals from the United States, the European Union, or Hong Kong with hepatocellular carcinoma (HCC) or who were at average or high-risk for HCC. Using a machine learning model that incorporated multifeature fragmentome data, the sensitivity for detecting cancer was 88% in an average-risk population at 98% specificity and 85% among high-risk individuals at 80% specificity. We validated these results in an independent population. cfDNA fragmentation changes reflected genomic and chromatin changes in liver cancer, including from transcription factor binding sites. These findings provide a biological basis for changes in cfDNA fragmentation in patients with liver cancer and provide an accessible approach for noninvasive cancer detection. Significance: There is a great need for accessible and sensitive screening approaches for HCC worldwide. We have developed an approach for examining genome-wide cfDNA fragmentation features to provide a high-performing and cost-effective approach for liver cancer detection. See related commentary Rolfo and Russo, p. 532. This article is highlighted in the In This Issue feature, p. 517

4 March 2025 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
DBDaniel C. Bruhm
Daniel C. Bruhm
NVNicholas A. Vulpescu
Nicholas A. Vulpescu
ZFZachariah H. Foda
Zachariah H. Foda
JPJillian Phallen
Jillian Phallen
RSRobert B. Scharpf
Robert B. Scharpf
VVVictor E. Velculescu
Victor E. Velculescu

30 September 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JMJamie E. Medina
Jamie E. Medina
AAAkshaya V. Annapragada
Akshaya V. Annapragada
PLPien Lof
Pien Lof
SSSarah Short
Sarah Short
ABAdrianna L. Bartolomucci
Adrianna L. Bartolomucci
VVVictor E. Velculescu
Victor E. Velculescu
Ovarian cancer is a leading cause of death for women worldwide, in part due to ineffective screening methods. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome and protein biomarker [cancer antigen 125 (CA-125) and human epididymis protein 4 (HE4)] analyses to evaluate 591 women with ovarian cancer, with benign adnexal masses, or without ovarian lesions. Using a machine learning model with the combined features, we detected ovarian cancer with specificity >99% and sensitivities of 72%, 69%, 87%, and 100% for stages I to IV, respectively. At the same specificity, CA-125 alone detected 34%, 62%, 63%, and 100%, and HE4 alone detected 28%, 27%, 67%, and 100% of ovarian cancers for stages I to IV, respectively. Our approach differentiated benign masses from ovarian cancers with high accuracy (AUC = 0.88, 95% confidence interval, 0.83–0.92). These results were validated in an independent population. These findings show that integrated cfDNA fragmentome and protein analyses detect ovarian cancers with high performance, enabling a new accessible approach for noninvasive ovarian cancer screening and diagnostic evaluation. Significance: There is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that evaluates cfDNA fragmentomes and protein biomarkers to detect ovarian cancer.

23 May 2025 in Science Advances
Verified
Journal Article
Open access
CHCarolyn Hruban
Carolyn Hruban
DBDaniel C. Bruhm
Daniel C. Bruhm
ICInna Markovna Markovna Chen
Inna Markovna Markovna Chen
SKShashikant Koul
Shashikant Koul
AAAkshaya V. Annapragada
Akshaya V. Annapragada
VVVictor E. Velculescu
Victor E. Velculescu
Determining response to therapy for patients with pancreatic cancer can be challenging. We evaluated methods for assessing therapeutic response using cell-free DNA (cfDNA) in plasma from patients with metastatic pancreatic cancer in the CheckPAC trial (NCT02866383). Patients were evaluated before and after initiation of therapy using tumor-informed plasma whole-genome sequencing (WGMAF) and tumor-independent genome-wide cfDNA fragmentation profiles and repeat landscapes (ARTEMIS-DELFI). Using WGMAF, molecular responders had a median overall survival (OS) of 319 days compared to 126 days for nonresponders [hazard ratio (HR) = 0.29, 95% confidence interval (CI) = 0.11–0.79, P = 0.011]. For ARTEMIS-DELFI, patients with low scores after therapy initiation had longer median OS than patients with high scores (233 versus 172 days, HR = 0.12, 95% CI = 0.046–0.31, P < 0.0001). We validated ARTEMIS-DELFI in patients with pancreatic cancer in the PACTO trial (NCT02767557). These analyses suggest that noninvasive mutation and fragmentation-based cfDNA approaches can identify therapeutic response of individuals with pancreatic cancer.

15 April 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JMJohn A. Morris
John A. Morris
JKJohn P. Kemp
John P. Kemp
SYScott E. Youlten
Scott E. Youlten
LLLaetitia Laurent
Laetitia Laurent
JLJohn G. Logan
John G. Logan
JRJ. Brent Richards
J. Brent Richards
In the version of this article initially published, in Fig. 5a, the data in the right column of ‘DAAM2 gRNA1’ were incorrectly plotted as circles indicating ‘untreated’ rather than as squares indicating ‘treated’. The error has been corrected in the HTML and PDF versions of the article.